Michelle L. O'Donoghue

2 months ago | medscape.com | Michelle L. O'Donoghue |Sunil V. Rao

This transcript has been edited for clarity. Michelle L. O'Donoghue, MD, MPH: This is Dr Michelle O'Donoghue, reporting for Medscape. Joining me today is Dr Sunil Rao, who is the director of interventional cardiology at the NYU Langone Health System. Importantly, he was also the chair of the recently released 2025 ACS guidelines. I served as vice chair, which was a pleasure to work with you on this.

Nov 17, 2024 | healio.com | Regina Schaffer |Richard Smith |Michelle L. O'Donoghue |Dean Kereiakes

You've successfully added CHD/Prevention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Large LDL reductions were maintained long term with lerodalcibep, a monthly PCSK9 inhibitor. Results were similar across subgroups and people with heterozygous familial hypercholesterolemia.

Apr 22, 2024 | medscape.com | Michelle L. O'Donoghue |Sunil V. Rao

This transcript has been edited for clarity. Michelle L. O'Donoghue, MD, MPH: Hi. This is Dr Michelle O'Donoghue, reporting for Medscape. Joining me today is Sunil Rao. He is a professor of medicine at NYU Grossman, as well as director of interventional cardiology at NYU Langone. Welcome, Sunil. Thanks for joining me today. Sunil V. Rao, MD: Thanks for having me.

Dec 11, 2023 | medscape.com | Michelle L. O'Donoghue |Sekar Kathiresan

This transcript has been edited for clarity. Michelle L. O'Donoghue, MD, MPH: Hi. This is Dr Michelle O'Donoghue, reporting for Medscape. I'm here at the American Heart Association meeting, and one of the interesting stories that we're going to be talking about is that of gene editing. Joining me to discuss this is Dr Sekar Kathiresan. He's the co-founder and the chief executive officer of Verve, and they presented some very interesting results.

Nov 17, 2023 | radcliffecardiology.com | Harriette Van Spall |Jeff S. Healey |Michelle L. O'Donoghue |Steven Nissen

AHA 2023 —  Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742). The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is to investigate the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a).